OncoMatch/Clinical Trials/NCT05846880
VitD3 Supplementation in Patients With Multiple Myeloma
Is NCT05846880 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including Lenalidomide and Maintenance Vitamin D for multiple myeloma.
Treatment: Lenalidomide · Maintenance Vitamin D · No maintenance Vitamin D — The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ZUBROD/ECOG 0–2
Zubrod/ECOG Performance Status 2
Prior therapy
Must have received: systemic induction therapy — prior to ASCT
systemic induction therapy prior to ASCT
Cannot have received: allograft
Prior allograft
Cannot have received: organ transplant requiring immunosuppressive therapy
prior organ transplant requiring immunosuppressive therapy
Cannot have received: autologous stem cell transplant
have already received a previous autologous transplantation (e.g., requiring second ASCT at time of screening)
Cannot have received: investigational agent
Received any investigational agents within 14 days prior to registration
Lab requirements
Kidney function
creatinine clearance (CrCl) 10 mL/min., as measured by a 24-hour urine collection, or estimated by the Cockcroft and Gault formula
Liver function
Total bilirubin 1.5 x IULN and AST and ALT 3.0 x IULN
Patients must have evidence of adequate renal function ... CrCl 10 mL/min ... adequate hepatic function ... Total bilirubin 1.5 x IULN and AST and ALT 3.0 x IULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgia Cancer Center at Augusta University · Augusta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05846880 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allograft, organ transplant requiring immunosuppressive therapy, autologous stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages